Human epidermal growth factor receptor 2/neu expression in urothelial carcinomas.
Introduction: Urothelial carcinomas of the bladder are more common in males, making them the sixth-most common cancer in men and the tenth-most common cancer overall, worldwide. Current guidelines do not recommend routine testing for human epidermal growth factor receptor (HER2/neu) expression on th...
| Publicado en: | Indian Journal of Urology Vol. 40; no. 1; pp. 44 - 49 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | pictorial research tables/charts Journal Article |
| Publicado: |
Wolters Kluwer India Pvt Ltd
Jan-Mar2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=174723388&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 174723388 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09701591 1KUG jtl: Indian Journal of Urology issn: 09701591 maglogo: N pubinfo: dt: Jan-Mar2024 vid: 40 iid: 1 pid: 16919 pub: Wolters Kluwer India Pvt Ltd artinfo: ui: 174723388 174723388 174723388 10.4103/iju.iju_287_23 174723388 ppf: 44 ppct: 5 formats: fmt: @attributes: type: P tig: atl: Human epidermal growth factor receptor 2/neu expression in urothelial carcinomas. aug: au: Soudamini, Arsha Balakrishnan Nalwa, Aasma Choudhary, Gautam Ram Bharti, Jyotsna Naresh Rao, Meenakshi Elhence, Poonam Abhay Pandey, Himanshu Goel, Akhil Dhanesh affil: Departments of Pathology and Lab Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India sug: subj: Epidermal Growth Factor Receptors Carcinoma, Transitional Cell Non-Muscle Invasive Bladder Neoplasms Gene Expression Human In Situ Hybridization, Fluorescence Fisher's Exact Test Gene Amplification Immunohistochemistry Female Male Female Male ab: Introduction: Urothelial carcinomas of the bladder are more common in males, making them the sixth-most common cancer in men and the tenth-most common cancer overall, worldwide. Current guidelines do not recommend routine testing for human epidermal growth factor receptor (HER2/neu) expression on the biopsy specimens of patients with urothelial carcinoma. This study was aimed at determining the expression pattern of HER2/neu and its usefulness in muscle-invasive and nonmuscle-invasive urothelial carcinoma. Methods: HER2/neu expression was assessed in 89 specimens of urothelial cancer by immunohistochemistry (IHC), and equivocal cases were subjected to fluorescent in situ hybridization (FISH). Results: On IHC for HER2/neu, 17.9% (7/39) of the muscle-invasive bladder cancers (MIBCs) showed a 3+ expression, whereas 22% (11/50) of the non-muscle invasive cancers were positive with a score of 3+. A significant correlation between HER2/neu status and muscle invasion could not be established in the current study (P = 0.74, Fisher's exact test). Three cases of muscle-invasive (7.7%) and 2 cases (4%) among nonmuscle invasive cancers showed equivocal expression. All the cases with equivocal (2+) expression on IHC were subjected to FISH and none showed gene amplification on hybridization and were considered as negative. Conclusion: Overexpression of HER-2/neu was seen in 17.9% of MIBCs and 22% of non-MIBCs. There are no norms for routine testing of HER2/neu expression in the biopsy specimens of urothelial carcinoma. There is an unmet need to establish guidelines for HER2/neu scoring, similar to that for breast and gastric cancers, to determine the proportion of positive cases and help in identification of those who may benefit from targeted therapies. pubtype: Academic Journal doctype: pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|